SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-30. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Accords == On February 19, 2015, representatives from the Malian government and the Coordination of Azawad Movements (CMA) agreed upon a new document, including the cessation of hostilities, as negotiations to end the broader war continued in Algiers. On March 1, a mediation agreement was proposed by Algeria, which was accepted by Mali and pro-government militias. The CMA asked for some time to consider the agreement, as there were no propositions for autonomy or federalism for northern Mali, which angered a large portion of Tuareg rebels. The CMA announced their refusal to sign the agreement on April 10. On April 27, the pro-government GATIA and Arab Movement of Azawad (MAA) captured Menaka, initiating new clashes between Tuareg rebels and the pro-government militias. On May 10, the CMA initialized the agreement, but did not sign the text. The peace agreement was signed on May 15 in Bamako by the Malian government, representatives of pro-government militias, and representatives from Algeria, Burkina Faso, Mauritania, Niger, Nigeria, Chad, the African Union, the United Nations, ECOWAS, the Organisation of Islamic Cooperation, the European Union, and France. No CMA representatives were present for the signing on May 15. That same day, fighting broke out near Menaka. Under pressure from international organizations, the CMA finally signed the agreement in Bamako on June 20. The CMA's representative was Sidi Brahim Ould Sidati, a leader of the MAA.
== Medical uses == Gepirone is indicated for the treatment of major depressive disorder (MDD) in adults. Of 15 clinical trials of gepirone for major depressive disorder submitted to the U.S. Food and Drug Administration (FDA), three were excluded for methodological reasons, three were deemed "failed" and "uninformative", seven were deemed negative and did not demonstrate effectiveness, and two were deemed positive and did show effectiveness. Two positive trials are needed for FDA drug approval, with this being the case regardless of the number of negative trials. In the two positive trials of gepirone for depression, the drug significantly outperformed placebo in terms of depressive symptom reduction and showed effect sizes similar to those of other approved antidepressants. In both trials, gepirone reduced depressive symptoms by about 2.5 points more than placebo on the 52-point Hamilton Depression Rating Scale (17-item version or HAMD-17). The baseline depression scores in the trials ranged from 22.7 to 24.2 in the different patient groups.
==== Argentina ==== In Argentina, cider, or sidra is by far the most popular alcoholic carbonated drink during the Christmas and New Year holidays. It has traditionally been considered the choice of the middle and lower classes (along with ananá fizz and pineapple juice), whereas the higher classes would rather go for champagne or local sparkling wines for their Christmas or New Year toast. Popular commercial brands of cider are Real, La Victoria, "Rama Caida", Tunuyan. It was traditionally marketed in 0.72-litre glass bottles, similar to Champagne bottles, and PET bottles for the lower-end brands. However, cider had a strong growth and is becoming a year-round beverage. Most brands now offer half-litre cans, and new flavours such as berries, peer, and some flavoured with plants such as elderberry and cardamom.
During a match against Borussia Mönchengladbach in 1996, Wenger presided over Rice's caretaker duties at Arsenal, and ordered the team to switch from their preferred 3–5–2 formation to 4–4–2. The tactical change did not have its desired effect, as Arsenal lost the game having led before Wenger's half-time instruction. For much of the 1996–97 season, Arsenal continued to play 3–5–2 as it was the only formation the defenders were comfortable with, as well as injuries unsettling the side. In Wenger's second season at the club, he reinstated 4–4–2 and focused on strengthening the front six, by signing wingers Overmars and Luís Boa Morte and partnering Vieira with Petit. According to Jonathan Wilson, the system was similar to 4–3–3, as Overmars often pushed higher up the field and Parlour played alongside Vieira and Petit to solidify the midfield. Needing to compensate deficiencies in attack the following season, Wenger relied on his experienced defence to direct games, which conceded 17 goals in 38 league matches. From then on, Wenger deployed an unconventional 4–4–2 with a greater emphasis on attack and movement; his teams between 2001 and 2004 were dominant on the left flank. By the 2005–06 season, clubs in England were increasingly in favour of using the 4–5–1 system. Wenger, having earlier suggested he would never resort to a negative system, later adopted the formation for Champions League matches. The decision to pack the midfield and play a lone striker resulted in Arsenal reaching the final.
Sources: en.wikipedia.org
=== Prostate surgery === The preservation of both neurovascular bundles during nerve-sparing (NS) radical prostatectomy improves urinary continence and erectile function. Consequently, NS is recommended in elderly men and those with pre-existing erectile dysfunction, whom many surgeons would previously have only offered non-NS surgery. It was also found that during surgeries in which neurovascular bundles are preserved, the frequency of positive margins were only 5.8 percent.
Maya Cave of "II Anlage" (Cave 205) has been carbon-dated to the 6th–7th century CE. The cave has an inscriptions in Sanskrit mentioning the King of Kucha Anantavarma. He is shown accompanied by two armed attendants.
Libraries of peptide aptamers have been used as "mutagens", in studies in which an investigator introduces a library that expresses different peptide aptamers into a cell population, selects for a desired phenotype, and identifies those aptamers that cause the phenotype. The investigator then uses those aptamers as baits, for example in yeast two-hybrid screens to identify the cellular proteins targeted by those aptamers. Such experiments identify particular proteins bound by the aptamers, and protein interactions that the aptamers disrupt, to cause the phenotype. In addition, peptide aptamers derivatized with appropriate functional moieties can cause specific post-translational modification of their target proteins, or change the subcellular localization of the targets.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.